Literature DB >> 20226957

Aldosterone and mineralocorticoid receptors in the cardiovascular system.

John W Funder1.   

Abstract

Aldosterone is currently thought to exert its physiologic effects by activating epithelial mineralocorticoid receptors, and its pathologic effects on the cardiovascular system via mineralocorticoid receptors in the heart and blood vessels. Recent studies have extended this understanding to include a reevaluation of the roles of aldosterone and mineralocorticoid receptor activation in blood pressure control; the rapid, nongenomic effects of aldosterone; the role of cortisol as a mineralocorticoid receptor agonist under conditions of redox change/tissue damage/reactive oxygen species generation; the growing consensus that primary aldosteronism accounts for approximately 10% of all essential hypertension; recent new insights into the cardioprotective role of spironolactone; and the development of third- and fourth-generation mineralocorticoid receptor antagonists for use in cardiovascular and other inflammatory disease. These findings on aldosterone action and mineralocorticoid receptor blockade are analyzed in the context of the prevention and treatment of cardiovascular disease. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20226957     DOI: 10.1016/j.pcad.2009.12.003

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  25 in total

1.  Different polymorphisms of the mineralocorticoid receptor gene are associated with either glucocorticoid or mineralocorticoid levels in hypertension.

Authors:  Bei Sun; Bindu Chamarthi; Jonathan S Williams; Alexander W Krug; Jessica Lasky-Su; Benjamin A Raby; Paul N Hopkins; Xavier Jeunemaitre; Claudio Ferri; Gordon H Williams
Journal:  J Clin Endocrinol Metab       Date:  2012-06-20       Impact factor: 5.958

2.  Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure.

Authors:  Matthew A Bailey; Eilidh Craigie; Dawn E W Livingstone; Yuri V Kotelevtsev; Emad A S Al-Dujaili; Christopher J Kenyon; John J Mullins
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

3.  Systolic heart failure in a patient with primary aldosteronism.

Authors:  Chikezie Alvarez; Vinuta Mohan
Journal:  BMJ Case Rep       Date:  2018-06-08

4.  Impressive results for aldosterone antagonists in mild heart failure.

Authors:  JoAnn Lindenfeld
Journal:  Curr Cardiol Rep       Date:  2011-06       Impact factor: 2.931

Review 5.  The Pharmacology of Autonomic Failure: From Hypotension to Hypertension.

Authors:  Italo Biaggioni
Journal:  Pharmacol Rev       Date:  2017-01       Impact factor: 25.468

6.  Neurohormonal Blockade in Heart Failure.

Authors:  Thomas G von Lueder; Dipak Kotecha; Dan Atar; Ingrid Hopper
Journal:  Card Fail Rev       Date:  2017-04

7.  Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.

Authors:  Min Zhao; Isabelle Célérier; Elodie Bousquet; Jean-Claude Jeanny; Laurent Jonet; Michèle Savoldelli; Olivier Offret; Antoine Curan; Nicolette Farman; Frédéric Jaisser; Francine Behar-Cohen
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

8.  Endoplasmic reticulum stress-mediated aldosterone-induced apoptosis in vascular endothelial cells.

Authors:  Jin-Ping Lu; Xia Li; Ya-Lei Jin; Mei-Xiang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

9.  Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males.

Authors:  Alexander W Krug; Lissy Stelzner; Ajaykumar D Rao; Andrew H Lichtman; Gordon H Williams; Gail K Adler
Journal:  Metabolism       Date:  2012-09-21       Impact factor: 8.694

Review 10.  New medical therapies for heart failure.

Authors:  Thomas G von Lueder; Henry Krum
Journal:  Nat Rev Cardiol       Date:  2015-09-29       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.